177 related articles for article (PubMed ID: 25583207)
1. DNA helicases FANCM and DDX11 are determinants of PARP inhibitor sensitivity.
Stoepker C; Faramarz A; Rooimans MA; van Mil SE; Balk JA; Velleuer E; Ameziane N; Te Riele H; de Winter JP
DNA Repair (Amst); 2015 Feb; 26():54-64. PubMed ID: 25583207
[TBL] [Abstract][Full Text] [Related]
2. Efficient deletion of normal Brca2-deficient intestinal epithelium by poly(ADP-ribose) polymerase inhibition models potential prophylactic therapy.
Hay T; Jenkins H; Sansom OJ; Martin NM; Smith GC; Clarke AR
Cancer Res; 2005 Nov; 65(22):10145-8. PubMed ID: 16287996
[TBL] [Abstract][Full Text] [Related]
3. Warsaw Breakage Syndrome associated DDX11 helicase resolves G-quadruplex structures to support sister chromatid cohesion.
van Schie JJM; Faramarz A; Balk JA; Stewart GS; Cantelli E; Oostra AB; Rooimans MA; Parish JL; de Almeida Estéves C; Dumic K; Barisic I; Diderich KEM; van Slegtenhorst MA; Mahtab M; Pisani FM; Te Riele H; Ameziane N; Wolthuis RMF; de Lange J
Nat Commun; 2020 Aug; 11(1):4287. PubMed ID: 32855419
[TBL] [Abstract][Full Text] [Related]
4. Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi Anemia genes, only FANCD1/BRCA2 plays a major role in high-risk breast cancer predisposition.
García MJ; Fernández V; Osorio A; Barroso A; Fernández F; Urioste M; Benítez J
Carcinogenesis; 2009 Nov; 30(11):1898-902. PubMed ID: 19737859
[TBL] [Abstract][Full Text] [Related]
5. Targeting DDX11 promotes PARP inhibitor sensitivity in hepatocellular carcinoma by attenuating BRCA2-RAD51 mediated homologous recombination.
Cao K; Wang R; Li L; Liao Y; Hu X; Li R; Liu X; Xiong XD; Wang Y; Liu X
Oncogene; 2024 Jan; 43(1):35-46. PubMed ID: 38007537
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.
Evers B; Drost R; Schut E; de Bruin M; van der Burg E; Derksen PW; Holstege H; Liu X; van Drunen E; Beverloo HB; Smith GC; Martin NM; Lau A; O'Connor MJ; Jonkers J
Clin Cancer Res; 2008 Jun; 14(12):3916-25. PubMed ID: 18559613
[TBL] [Abstract][Full Text] [Related]
7. A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity.
Lord CJ; McDonald S; Swift S; Turner NC; Ashworth A
DNA Repair (Amst); 2008 Dec; 7(12):2010-9. PubMed ID: 18832051
[TBL] [Abstract][Full Text] [Related]
8. Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers.
Lombardi AJ; Hoskins EE; Foglesong GD; Wikenheiser-Brokamp KA; Wiesmüller L; Hanenberg H; Andreassen PR; Jacobs AJ; Olson SB; Keeble WW; Hays LE; Wells SI
Clin Cancer Res; 2015 Apr; 21(8):1962-72. PubMed ID: 25609062
[TBL] [Abstract][Full Text] [Related]
9. Warsaw breakage syndrome, a cohesinopathy associated with mutations in the XPD helicase family member DDX11/ChlR1.
van der Lelij P; Chrzanowska KH; Godthelp BC; Rooimans MA; Oostra AB; Stumm M; Zdzienicka MZ; Joenje H; de Winter JP
Am J Hum Genet; 2010 Feb; 86(2):262-6. PubMed ID: 20137776
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?
Bouwman P; Jonkers J
Clin Cancer Res; 2014 Feb; 20(3):540-7. PubMed ID: 24270682
[TBL] [Abstract][Full Text] [Related]
11. Cellular characterization of cells from the Fanconi anemia complementation group, FA-D1/BRCA2.
Godthelp BC; van Buul PP; Jaspers NG; Elghalbzouri-Maghrani E; van Duijn-Goedhart A; Arwert F; Joenje H; Zdzienicka MZ
Mutat Res; 2006 Oct; 601(1-2):191-201. PubMed ID: 16920162
[TBL] [Abstract][Full Text] [Related]
12. Interaction of the Warsaw breakage syndrome DNA helicase DDX11 with the replication fork-protection factor Timeless promotes sister chromatid cohesion.
Cortone G; Zheng G; Pensieri P; Chiappetta V; Tatè R; Malacaria E; Pichierri P; Yu H; Pisani FM
PLoS Genet; 2018 Oct; 14(10):e1007622. PubMed ID: 30303954
[TBL] [Abstract][Full Text] [Related]
13. Warsaw breakage syndrome DDX11 helicase acts jointly with RAD17 in the repair of bulky lesions and replication through abasic sites.
Abe T; Ooka M; Kawasumi R; Miyata K; Takata M; Hirota K; Branzei D
Proc Natl Acad Sci U S A; 2018 Aug; 115(33):8412-8417. PubMed ID: 30061412
[TBL] [Abstract][Full Text] [Related]
14. The Warsaw breakage syndrome-related protein DDX11 is required for ribosomal RNA synthesis and embryonic development.
Sun X; Chen H; Deng Z; Hu B; Luo H; Zeng X; Han L; Cai G; Ma L
Hum Mol Genet; 2015 Sep; 24(17):4901-15. PubMed ID: 26089203
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibitors: targeting the right patients.
Azvolinsky A
J Natl Cancer Inst; 2012 Dec; 104(24):1851-2. PubMed ID: 23231976
[No Abstract] [Full Text] [Related]
16. DDX11 loss causes replication stress and pharmacologically exploitable DNA repair defects.
Jegadesan NK; Branzei D
Proc Natl Acad Sci U S A; 2021 Apr; 118(17):. PubMed ID: 33879618
[No Abstract] [Full Text] [Related]
17. The role of poly adenosine diphosphate ribose polymerase inhibitors in breast and ovarian cancer: current status and future directions.
Chionh F; Mitchell G; Lindeman GJ; Friedlander M; Scott CL
Asia Pac J Clin Oncol; 2011 Sep; 7(3):197-211. PubMed ID: 21884432
[TBL] [Abstract][Full Text] [Related]
18. Evidence for complete epistasis of null mutations in murine Fanconi anemia genes Fanca and Fancg.
van de Vrugt HJ; Koomen M; Bakker S; Berns MA; Cheng NC; van der Valk MA; de Vries Y; Rooimans MA; Oostra AB; Hoatlin ME; Te Riele H; Joenje H; Arwert F
DNA Repair (Amst); 2011 Dec; 10(12):1252-61. PubMed ID: 22036606
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.
Yap TA; Sandhu SK; Carden CP; de Bono JS
CA Cancer J Clin; 2011; 61(1):31-49. PubMed ID: 21205831
[TBL] [Abstract][Full Text] [Related]
20. Individuals with FANCM biallelic mutations do not develop Fanconi anemia, but show risk for breast cancer, chemotherapy toxicity and may display chromosome fragility.
Catucci I; Osorio A; Arver B; Neidhardt G; Bogliolo M; Zanardi F; Riboni M; Minardi S; Pujol R; Azzollini J; Peissel B; Manoukian S; De Vecchi G; Casola S; Hauke J; Richters L; Rhiem K; Schmutzler RK; Wallander K; Törngren T; Borg Å; Radice P; Surrallés J; Hahnen E; Ehrencrona H; Kvist A; Benitez J; Peterlongo P
Genet Med; 2018 Apr; 20(4):452-457. PubMed ID: 28837162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
